A population-based study was conducted on 256 southern Chinese with cervical intraepithelial neoplasia grade III (CIN III) or invasive cervical cancer (ICC) and on 258 controls to examine the associations between HLA-B alleles, infection with high-risk human papillomaviruses (HPVs) and the development of cervical neoplasia. HLA-B15 was found to be protective for CIN III/ICC overall (p(corrected) = 0.003), and for HPV52-positive CIN III/ICC (p(corrected) = 0.003). A marginal protective effect of B15 was observed for HPV16-positive CIN III/ICC, but no significant associations were revealed for HPV18- or HPV58-positive cases. None of the HLA-B alleles were found to confer an increased risk for cervical neoplasia. HLA-B15 is common among Asian for whom HPV52, a worldwide uncommon HPV type, also exists in a relatively high prevalence. It would also be worthwhile to assess the association between HLA-B15, HPV52 and cervical cancer in other Asian populations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ijc.21528 | DOI Listing |
Int J Immunogenet
January 2025
Department of Clinical Haematology and Medical Oncology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
High degree of variability in human leukocyte antigens (HLAs) system restricts availability of histocompatible HLA-matched-related donors, thus increasing reliance on worldwide bone marrow registries network. Nevertheless, due to limited coverage/accessibility/affordability of some ethnicities in these registries, haploidentical haematopoietic stem cell transplantation (HSCT) emerged as an alternative option, though with allorecognition-mediated graft versus host disease (GvHD) (>40% cases). A dimorphism [-21 methionine (M) or threonine (T)] in HLA-B leader peptide (exon 1) which differentially influences its HLA-E binding, plausibly regulates natural killer cell functionality, affecting GvHD vulnerability and clinically in practice for donor selection.
View Article and Find Full Text PDFHLA
January 2025
Department of Transfusion Research, Wuhan Blood Center, Wuhan, China.
HLA-B*15:245:02Q differs from HLA-B*15:01:01:01 by two nonsynonymous nucleotides exchanges in exon 3.
View Article and Find Full Text PDFHLA
January 2025
HLA and Histocompatibility Laboratory, CHRU de Nancy, Vandœuvre-lès-Nancy, France.
The new allele HLA-B*44:384 differs from HLA-B*44:02:01:01 by one non-synonymous nucleotide substitution in exon 2.
View Article and Find Full Text PDFHLA
January 2025
Department of Transfusion, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
HLA-B*37:114 has a single non-synonymous change from HLA-B*37:01:01:01 changing residue 163 from Threonine to Lysine'.
View Article and Find Full Text PDFBiomedica
December 2024
Servicio de Reumatología e Inmunología, Hospital Militar Central, Bogotá, D. C., Colombia; Grupo de Inmunología Clínica Aplicada, Hospital Militar Central, Universidad Militar Nueva Granada, Bogotá, D. C., Colombia; Grupo de Inmunología Celular y Molecular - InmuBo, Universidad El Bosque, Bogotá, D. C., Colombia.
Introduction: Psoriatic arthritis is a complex disease, and human leukocyte antigens (HLA) are key to its development. Latin America and, specifically, Colombia, has scarce data about patients with psoriatic arthritis.
Objective: To describe the genotypic, allelic and haplotypic frequency of HLA alleles in psoriatic arthritis and associate them with clinical variables.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!